Incidence and patterns of rejection using different induction therapies in liver transplant recipients.
Elkashab
M
M
Liver Transplant Program, Toronto Hospital, University of Toronto, Canada.
Reizig
M
M
Greig
P D
PD
Cameron
R
R
Phillips
M J
MJ
Chung
S
S
Cattral
M
M
Levy
G
G
D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001707:Biopsy, Needle; D016572:Cyclosporine / Q000097:blood / Q000627:therapeutic use; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology* / Q000473:pathology / Q000628:therapy; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D015994:Incidence; D008111:Liver Function Tests; D016031:Liver Transplantation / Q000276:immunology* / Q000473:pathology / Q000502:physiology; D008297:Male; D008776:Methylprednisolone Hemisuccinate / Q000627:therapeutic use; D016853:Muromonab-CD3 / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D012189:Retrospective Studies
D000961:Antilymphocyte Serum; D016853:Muromonab-CD3; D008776:Methylprednisolone Hemisuccinate; D016572:Cyclosporine; D011241:Prednisone